

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597509
	Filing Date		2008-08-20
	First Named Inventor	Fredika Robertson	
	Art Unit	1647	
	Examiner Name	SAOUD, Christine J	
	Attorney Docket Number	22727/04421	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4373217		1983-02-15	Draenert	
	2	5011912		1991-04-30	Hopp et al.	
	3	5545806		1996-08-13	Lonberg et al.	
	4	5569825		1996-10-29	Lonberg et al.	
	5	6140073		2000-08-31	Bayne et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030114366	A1	2003-06-19	Martin et al.	
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add
FOREIGN PATENT DOCUMENTS						Remove

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597509
Filing Date	2008-08-20
First Named Inventor	Fredika Robertson
Art Unit	1647
Examiner Name	SAOUD, Christine J
Attorney Docket Number	22727/04421

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2005072417	WO	A2	2005-08-11	Robertson et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	International Search Report for WO 2005/072417 (PCT/US2005/002929), mailed February 4, 2009.	<input type="checkbox"/>
	2	Written Opinion for WO 2005/072417 (PCT/US2005/002929), mailed February 20, 2009.	<input type="checkbox"/>
	3	International Preliminary Report on Patentability for WO 2005/072417 (PCT/US2005/002929), mailed February 24, 2009.	<input type="checkbox"/>
	4	AFFARA, et al. "Vascular Endothelial Growth Factor as a Survival Factor in Tumor-Associated Angiogenesis", in vivo, (2004), Vol. 18, Pages 525-542.	<input type="checkbox"/>
	5	BATES, et al. "VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Is Down-Regulated in Renal Cell Carcinoma", Cancer Research, (2002), Vol. 62, No. 14, Pages 4123-4131.	<input type="checkbox"/>
	6	BATES, et al. "VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant Mechanism of Action, In vivo Effect On Angiogenesis and Endogenous Protein Expression", Cancer Research (2004), Vol. 64, No. 21, Pages 7822-7835.	<input type="checkbox"/>
	7	BORGSTROM, et al. "Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin", Anticancer Research (1999), Vol. 19, No. 5B, Pages 4203-4214.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597509
Filing Date	2008-08-20
First Named Inventor	Fredika Robertson
Art Unit	1647
Examiner Name	SAOUD, Christine J
Attorney Docket Number	22727/04421

8	CLAFFEY, et al. "Vascular Endothelial Growth Factor", The Journal of Biological Chemistry (1992), Vol. 267, No. 23, Pages 16317-16322.	<input type="checkbox"/>
9	CUI, et al. "Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein", Am. J. Physiol Renal Physiol. (2004), Vol. 286, No. 4, Pages F767-F773.	<input type="checkbox"/>
10	FERRARA, "Vascular Endothelial Growth Factor", European J. of Cancer (1996), Vol. 52A, No. 14, Pages 2413-2422.	<input type="checkbox"/>
11	GRUNSTEIN, et al. "Isoforms of Vascular Endothelial Growth Factor Act in a Coordinate Fashion to Recruit and Expand Tumor Vasculature", Molecular and Cellular Biology (2000), Vol. 20, No. 19, Pages 7282-7291.	<input type="checkbox"/>
12	HOPP, et al. "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification", Bio/Technology (1988), Vol. 6, Pages 1204-1210.	<input type="checkbox"/>
13	ITO, et al. "Hair follicle stem cells in the lower bulge form the secondary germ, a biochemically distinct but functionally equivalent progenitor cell population, at the termination of catagen", Differentiation (2004), Vol. 72, Pages 548-557.	<input type="checkbox"/>
14	LARRICK, et al. "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes from Single Hybridoma Cells", Bio/Technology (1989), Vol. 7, Page 934-938.	<input type="checkbox"/>
15	LIU, et al. "Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells", PNAS (1987), Vol. 84, Pages 3439-3443.	<input type="checkbox"/>
16	MANIATIS, et al. "Molecular Cloning (A Laboratory Manual)", Cold Spring Harbor Laboratory (1982), Pages 387-389.	<input type="checkbox"/>
17	MIHM, et al. "Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase", Br. J. Pharmacol. (2002), Vol. 135, No. 3, Pages 581-588.	<input type="checkbox"/>
18	NEEDLEMAN, et al. "A general method applicable to the search for similarities in the amino acid sequence of two proteins", J. Mol. Bio. (1970), Vol. 48, Pages 443-453.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10597509
Filing Date		2008-08-20
First Named Inventor	Fredika Robertson	
Art Unit	1647	
Examiner Name	SAOUD, Christine J	
Attorney Docket Number	22727/04421	

19	ORTIZ, et al. "Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects", PNAS (2003), Vol. 100, No. 14, Pages 8407-8411.	<input type="checkbox"/>
20	OZERDEM, et al "Early Contribution of Pericytes to Angiogenic Sprouting and Tube Formation", Angiogenesis (2003), Vol. 6, No. 3, Pages 241-249.	<input type="checkbox"/>
21	RIECHMANN, et al. "Reshaping human antibodies for therapy", Nature (1988), Vol. 332, Pages 323-327.	<input type="checkbox"/>
22	ROBERTSON, et al. "Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion", Carcinogenesis (1996), Vol. 17, No. 9, Pages 2053-2059.	<input type="checkbox"/>
23	ROBINSON, et al. "The splice variants of vascular endothelial growth factor (VEGF) and their receptors", J. of Cell Science (2001), Vol. 114, No. 5, Pages 853-865.	<input type="checkbox"/>
24	SONG, et al. "Angiogenic role for glycodelin in tumorigenesis", PNAS (2001), Vol. 96, No. 16, Pages 9265-9270.	<input type="checkbox"/>
25	SUGIHARA, et al. "A Novel Alternatively Spliced Form of murine Vascular Endothelial Growth Factor, VEGF 115**", The Journal of Biological Chemistry (1998), Vol. 273, No. 5, Pages 3033-3038.	<input type="checkbox"/>
26	TOBER, et al. "Comparative Expression of Novel Vascular Endothelial Growth Factor/Vascular Permeability Factor Transcripts in Skin, Papillomas, and Carcinomas of v-Ha-ras Tg.AC Transgenic Mice and FVB/N Mice", Biochemical and Biophysical Research Communications (1998), Vol. 247, Pages 644-653.	<input type="checkbox"/>
27	TREMPUS, et al. "Enrichment for Living Murine Keratinocytes from the Hair Follicle Bulge with the Cell Surface Marker CD34", J. Invest. Dermatol. (2003), Vol. 120, Pages 501-511.	<input type="checkbox"/>
28	WEINSTEIN, et al. "Cardiac Peroxynitrite Formation and Left Ventricular Dysfunction following Doxorubicin Treatment in Mice", J. Pharmacol. Exp. Ther. (2000), Vol. 294, No. 1, Pages 396-401.	<input type="checkbox"/>
29	WINTER, et al. "Humanized antibodies", TIPS (1993), Vol. 14, Pages 139-143.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597509
Filing Date	2008-08-20
First Named Inventor	Fredika Robertson
Art Unit	1647
Examiner Name	SAOUD, Christine J
Attorney Docket Number	22727/04421

30	WOOLARD, et al. "VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant: Mechanism of Action, In vivo Effect On Angiogenesis and Endogenous Protein Expression ", Cancer Research (2004), Vol. 64, No. 21, Pages 7822-7835.	<input type="checkbox"/>
31	ZHANG, et al. "Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse", Blood (2004), Vol. 103, No. 2, Pages 617-626.	<input type="checkbox"/>
32		<input type="checkbox"/>
33		<input type="checkbox"/>
34		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/Christine Saoud/	Date Considered	07/02/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./